Theratechnologies was founded in 1993. Scientists at Theratechnologies discovered EGRIFTA®(tesamorelin for injection) in 1995. For the next fifteen years, Theratechnologies pursued the development of this innovative treatment for lipodystrophy in people living with HIV. In 2010, Theratechnologies received a marketing authorization for EGRIFTA® from the Food and Drug Administration in the United States.
EGRIFTA® was first marketed by a third-party commercial partner in the United States. Then, in 2014, Theratechnologies made a strategic decision and reoriented its business model to become a commercial-stage biopharmaceutical company. This is when Theratechnologies regained commercial rights to EGRIFTA® in the United States.
This move gave Theratechnologies the means to look at other acquisitions which came shortly thereafter. The Company concluded an agreement to acquire the commercial rights to Trogarzo® in the United States, Europe, Canada, the Scandinavian countries, Russia, Israel and Switzerland. Trogarzo® was approved by the FDA in 2018 and was quickly adopted by hundreds of physicians to treat people living with HIV.
Trogarzo® was recently approved in Europe where it will be commercialized very soon but already several patients are being treated through various early access programs funded by local governments.
Theratechnologies is already looking beyond and working on the lifecycle of its commercialized products.
The Company announced its intention to develop tesamorelin, the active ingredient in EGRIFTA®, for the treatment of Non-Alcoholic Steatohepatitis (NASH) in people living with HIV.
Furthermore, new delivery methods are being investigated for Trogarzo® to make it even more patient friendly.
True to its commitment to provide solutions to unmet medical needs in niche market segments, Theratechnologies is also pursuing the development of a highly targeted oncology platform for various types of cancers.
